Overview
T. Y. Alvin Liu, M.D. is the James P. Gills, Jr. M.D., and Heather Gills Rising Professor of AI and the founding director of the Wilmer Precision Ophthalmology Center of Excellence. He is originally from Hong Kong, and speaks fluent Cantonese and Mandarin. He attended Phillips Exeter Academy in Exeter, New Hampshire, and graduated from Cornell University with a dual major in biology and economics. He received his M.D. from Columbia University in 2012, and completed his residency (2016) and fellowship (surgical and medical retina- 2018) at Johns Hopkins. He is subspecialty-trained in the medical and surgical treatment of vitreoretinal diseases, including age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vascular occlusion, retinal detachment, vitreous hemorrhage, epiretinal membrane and macular hole. Dr. Liu's research interests center on the application of artificial intelligence in the screening, diagnosis, prognostication and treatment of ophthalmic diseases, with a specific focus on vitreoretinal diseases such as age-related macular degeneration and diabetic retinopathy. In addition, he is involved in research on the pathogenesis of and treatment for pathologic myopia and the management of severe ocular trauma. Videos Dr. Tin Yan Alvin Liu Recent News Articles and Media Coverage AI Speeds Diabetic Retinopathy Diagnosis Without Specialist. Medscape August 28, 2018 AI Screening for Diabetic Retinopathy Moves to Retail Clinics. Medscape November 26, 2019 How Artificial Intelligence is Primed to Change Ophthalmology. Ophthalmology Advisor May 14, 2021 Medicine's first autonomous AI could prevent blindness due to diabetes. Stat News December 16, 2021 Innovations in Eye Care: How Technology is Transforming Ophthalmology. HealthTech November 29, 2022 Time to go multicultural. Retina Today March 1, 2023 How deep learning may play a role in predicting retinitis pigmentosa visual impairment. Ophthalmology Times March 14, 2023 AI in retinal diagnostics. Zhaoke Ophthalmology March 22, 2023 Macular Degeneration. Spotlight on Geographic Atrophy. Advances in Treatment. WebMD April 23, 2023 ARVO 2023: T.Y. Alvin Liu, MD discusses predictive AI and its application in ophthalmology. Modern Retina April 25, 2023 ASCRS: Prediction of imminent conversion to neovascular AMD using deep learning and 3D OCT volumes. OptometryTimes May 5, 2023 Adopting and regulating AI in healthcare. BNN Bloomberg May 29, 2023 AI could increase health equity and boost adherence to annual eye examination in patients with diabetes. Modern Retina June 21, 2023 As more Marylanders grow older, a debilitating eye disease is gaining ground. The Baltimore Banner June 26, 2023.
Dr. Liu is highly rated in 14 conditions, according to our data. His top areas of expertise are Usher Syndrome Type 2A, Cone Rod Dystrophy Amelogenesis Imperfecta, Cone-Rod Dystrophy, and Stargardt Macular Degeneration.
His clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
10710 Charter Drive, Suite 310, Suite 310, Columbia, MD 21044
1800 Orleans Street, Maumenee Lobby, Baltimore, MD 21287
10753 Falls Road, Pavilion II STE 455, Lutherville, MD 21093
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Brian Brooks is an Ophthalmologist in Washington, Washington, D.c.. Dr. Brooks is highly rated in 29 conditions, according to our data. His top areas of expertise are Coloboma, Albinism, Oculocutaneous Albinism, and Oculocutaneous Albinism Type 1.
The Johns Hopkins Hospital
Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is highly rated in 18 conditions, according to our data. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.
Emily Chew is an Ophthalmologist in Bethesda, Maryland. Dr. Chew is highly rated in 10 conditions, according to our data. Her top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Retinopathy, and Cataract Removal.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Adult-Onset Vitelliform Macular Dystrophy (AVMD)
- Age-Related Macular Degeneration (ARMD)
- Cone DystrophyDr. Liu isAdvanced. Learn about Cone Dystrophy.
- Cone Rod Dystrophy Amelogenesis Imperfecta
- Cone-Rod DystrophyDr. Liu isAdvanced. Learn about Cone-Rod Dystrophy.
- Diabetic RetinopathyDr. Liu isAdvanced. Learn about Diabetic Retinopathy.
- Experienced
- Choroid Plexus CarcinomaDr. Liu isExperienced. Learn about Choroid Plexus Carcinoma.
- EndophthalmitisDr. Liu isExperienced. Learn about Endophthalmitis.
- Geographic AtrophyDr. Liu isExperienced. Learn about Geographic Atrophy.
- NearsightednessDr. Liu isExperienced. Learn about Nearsightedness.
- NeuroretinitisDr. Liu isExperienced. Learn about Neuroretinitis.
- Retinal Artery OcclusionDr. Liu isExperienced. Learn about Retinal Artery Occlusion.